exatecan mesylate Recently Published Documents

Exatecan Mesylate Anhydrous

10.32388/bheizs ◽

2020 ◽

Author(s):

Keyword(s):

Exatecan Mesylate 171335-80-1

Sax's Dangerous Properties of Industrial Materials ◽

10.1002/0471701343.sdp37788 ◽

2012 ◽

Keyword(s):

A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer

Investigational New Drugs ◽

10.1007/s10637-005-2907-z ◽

2005 ◽

Vol 23 (5) ◽

pp. 479-484 ◽

Cited By ~ 14

Author(s):

Jaffer A. Ajani ◽

Chris Takimoto ◽

Carlos R. Becerra ◽

Alejandro Silva ◽

Luis Baez ◽

...

Keyword(s):

Gastric Cancer ◽

Phase Ii ◽

Pharmacokinetic Study ◽

Metastatic Gastric Cancer ◽

A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2004.06.047 ◽

2004 ◽

Vol 95 (1) ◽

pp. 114-119 ◽

Cited By ~ 5

Author(s):

A. Clamp ◽

M. Adams ◽

R. Atkinson ◽

E. Boven ◽

A.H. Calvert ◽

...

Keyword(s):

Ovarian Cancer ◽

Topoisomerase I ◽

Topoisomerase I Inhibitor ◽

Resistant Refractory ◽

A randomized phase III trial of DX-8951f (Exatecan Mesylate; DX) and Gemcitabine (GEM) vs. Gemcitabine alone in advanced pancreatic cancer (APC)

10.1200/jco.2004.22.90140.4006 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 4006-4006 ◽

Cited By ~ 2

Author(s):

E. M. O' Reilly ◽

G. K. Abou-Alfa ◽

R. Letourneau ◽

W. G. Harker ◽

M. Modiano ◽

...

Keyword(s):

Pancreatic Cancer ◽

Advanced Pancreatic Cancer ◽

Phase Iii ◽

Phase Iii Trial ◽

A phase I study of DX 8951f (exatecan mesylate for injection) in patients with renal dysfunction

10.1200/jco.2004.22.90140.2069 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 2069-2069

Author(s):

C. J. Sweeney ◽

M. W. Saif ◽

P. M. Lorusso ◽

M. P. Ducharme ◽

R. Demnati ◽

...

Keyword(s):

Phase I ◽

Renal Dysfunction ◽

Phase I Study ◽

A randomized phase III trial of DX-8951f (Exatecan Mesylate; DX) and Gemcitabine (GEM) vs. Gemcitabine alone in advanced pancreatic cancer (APC)

10.1200/jco.2004.22.14_suppl.4006 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 4006-4006 ◽

Cited By ~ 24

Author(s):

E. M. O' Reilly ◽

G. K. Abou-Alfa ◽

R. Letourneau ◽

W. G. Harker ◽

M. Modiano ◽

...

Keyword(s):

Pancreatic Cancer ◽

Advanced Pancreatic Cancer ◽

Phase Iii ◽

Phase Iii Trial ◽

A phase I study of DX 8951f (exatecan mesylate for injection) in patients with renal dysfunction

10.1200/jco.2004.22.14_suppl.2069 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 2069-2069 ◽

Cited By ~ 9

Author(s):

C. J. Sweeney ◽

M. W. Saif ◽

P. M. Lorusso ◽

M. P. Ducharme ◽

R. Demnati ◽

...

Keyword(s):

Phase I ◽

Renal Dysfunction ◽

Phase I Study ◽

A Phase II Study of Intravenous Exatecan Mesylate (DX-8951f) Administered Daily for Five Days Every Three Weeks to Patients with Metastatic Adenocarcinoma of the Colon or Rectum

Investigational New Drugs ◽

10.1023/b:drug.0000006174.87869.6b ◽

2004 ◽

Vol 22 (1) ◽

pp. 53-61 ◽

Cited By ~ 9

Author(s):

Melanie E. Royce ◽

Eric K. Rowinsky ◽

Paulo M. Hoff ◽

John Coyle ◽

Robert DeJager ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Metastatic Adenocarcinoma ◽

Adenocarcinoma Of The Colon ◽